他汀类药物与肾细胞癌的关系;系统综述与meta分析

IF 0.2 Q4 UROLOGY & NEPHROLOGY
P. Ramezannezhad, Mohammadreza Khosravifarsani
{"title":"他汀类药物与肾细胞癌的关系;系统综述与meta分析","authors":"P. Ramezannezhad, Mohammadreza Khosravifarsani","doi":"10.34172/jrip.2023.32192","DOIUrl":null,"url":null,"abstract":"Introduction: Renal cell carcinoma (RCC) is the most prevalent renal cancer in adults, with a rising global incidence. There has long been an ambiguity about the effect of statin administration on the incidence of RCC. The present meta-analysis aims to evaluate the relationship between statin usage and RCC. Materials and Methods: Cochrane, Web of Science, Scopus, and PubMed databases, as well as the Google Scholar search engine, were queried for relevant articles. The data were statistically analyzed by STATA 14 software. The significance level of the tests was considered P<0.05. Results: In 15 reviewed articles, 46 735 subjects used statin, and 673 752 did not. The odds ratio (OR) between statin usage and the risk incidence of RCC was 0.86 (OR: 0.86; 95% CI: 0.63, 1.17) overall and estimated as 0.94 (OR: 0.94; 95% CI: 0.69, 1.28) in males and 0.92 (OR: 0.92; 95% CI: 0.66, 1.28) in females. The odds ratio of statin administration and the incidence risk of RCC was 0.74 (OR: 0.74; 95% CI: 0.37, 1.49) in case-control and 0.96 (OR: 0.96; 95% CI: 0.79, 1.17) in cohort studies. In addition, the impact of statin usage on overall survival (OS) in RCC was 0.65 (HR: 0.65; 95% CI: 0.53, 0.80), and this relationship was statistically significant. However, the effect of statin usage was 0.68 (HR: 0.68; 95% CI: 0.45, 1.02) on progression-free survival (PFS) and 1.24 (OR: 1.24; 95% CI: 0.66, 2.32) on disease progression (DP), and these relationships were statistically non-significant. Conclusion: The OS of RCC patients was 35% higher in statin users than in non-users. However, no relationship between statin usage and the incidence risk of RCC was found. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (CRD42023393647).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis\",\"authors\":\"P. Ramezannezhad, Mohammadreza Khosravifarsani\",\"doi\":\"10.34172/jrip.2023.32192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Renal cell carcinoma (RCC) is the most prevalent renal cancer in adults, with a rising global incidence. There has long been an ambiguity about the effect of statin administration on the incidence of RCC. The present meta-analysis aims to evaluate the relationship between statin usage and RCC. Materials and Methods: Cochrane, Web of Science, Scopus, and PubMed databases, as well as the Google Scholar search engine, were queried for relevant articles. The data were statistically analyzed by STATA 14 software. The significance level of the tests was considered P<0.05. Results: In 15 reviewed articles, 46 735 subjects used statin, and 673 752 did not. The odds ratio (OR) between statin usage and the risk incidence of RCC was 0.86 (OR: 0.86; 95% CI: 0.63, 1.17) overall and estimated as 0.94 (OR: 0.94; 95% CI: 0.69, 1.28) in males and 0.92 (OR: 0.92; 95% CI: 0.66, 1.28) in females. The odds ratio of statin administration and the incidence risk of RCC was 0.74 (OR: 0.74; 95% CI: 0.37, 1.49) in case-control and 0.96 (OR: 0.96; 95% CI: 0.79, 1.17) in cohort studies. In addition, the impact of statin usage on overall survival (OS) in RCC was 0.65 (HR: 0.65; 95% CI: 0.53, 0.80), and this relationship was statistically significant. However, the effect of statin usage was 0.68 (HR: 0.68; 95% CI: 0.45, 1.02) on progression-free survival (PFS) and 1.24 (OR: 1.24; 95% CI: 0.66, 2.32) on disease progression (DP), and these relationships were statistically non-significant. Conclusion: The OS of RCC patients was 35% higher in statin users than in non-users. However, no relationship between statin usage and the incidence risk of RCC was found. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (CRD42023393647).\",\"PeriodicalId\":16950,\"journal\":{\"name\":\"Journal of Renal Injury Prevention\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Renal Injury Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jrip.2023.32192\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2023.32192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:肾细胞癌(RCC)是癌症最常见的肾肿瘤,全球发病率不断上升。长期以来,他汀类药物对肾细胞癌发病率的影响一直存在歧义。本荟萃分析旨在评估他汀类药物的使用与肾细胞癌之间的关系。材料和方法:在Cochrane、Web of Science、Scopus和PubMed数据库以及Google Scholar搜索引擎中查询相关文章。数据采用STATA14软件进行统计分析。检验的显著性水平被认为是P<0.05。结果:在15篇综述文章中,46735名受试者使用了他汀类药物,673752名未使用。他汀类药物使用与肾细胞癌风险发生率之间的比值比(OR)总体为0.86(OR:0.86;95%CI:0.63,1.17),男性估计为0.94(OR:0.94;95%CI:0.69,1.28),女性估计为0.92(OR:0.92;95%CI:0.66,1.28)。他汀类药物给药与RCC发病风险的比值比在病例对照研究中为0.74(OR:0.74;95%CI:0.371.49),在队列研究中为0.96(OR:0.96;95%CI:0.791.17)。此外,他汀类药物使用对RCC总生存率(OS)的影响为0.65(HR:0.65;95%CI:0.53,0.80),这种关系具有统计学意义。然而,他汀类药物的使用对无进展生存期(PFS)的影响为0.68(HR:0.68;95%CI:0.451.02),对疾病进展期(DP)的影响是1.24(OR:1.24;95%CI:0.66,2.32),这些关系在统计学上不显著。结论:他汀类药物使用者的肾细胞癌患者OS比非使用者高35%。然而,他汀类药物的使用与肾细胞癌的发病风险之间没有关系。荟萃分析注册:本研究基于PRISMA检查表编制,其方案已在PROSPERO网站(CRD42023393647)上注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis
Introduction: Renal cell carcinoma (RCC) is the most prevalent renal cancer in adults, with a rising global incidence. There has long been an ambiguity about the effect of statin administration on the incidence of RCC. The present meta-analysis aims to evaluate the relationship between statin usage and RCC. Materials and Methods: Cochrane, Web of Science, Scopus, and PubMed databases, as well as the Google Scholar search engine, were queried for relevant articles. The data were statistically analyzed by STATA 14 software. The significance level of the tests was considered P<0.05. Results: In 15 reviewed articles, 46 735 subjects used statin, and 673 752 did not. The odds ratio (OR) between statin usage and the risk incidence of RCC was 0.86 (OR: 0.86; 95% CI: 0.63, 1.17) overall and estimated as 0.94 (OR: 0.94; 95% CI: 0.69, 1.28) in males and 0.92 (OR: 0.92; 95% CI: 0.66, 1.28) in females. The odds ratio of statin administration and the incidence risk of RCC was 0.74 (OR: 0.74; 95% CI: 0.37, 1.49) in case-control and 0.96 (OR: 0.96; 95% CI: 0.79, 1.17) in cohort studies. In addition, the impact of statin usage on overall survival (OS) in RCC was 0.65 (HR: 0.65; 95% CI: 0.53, 0.80), and this relationship was statistically significant. However, the effect of statin usage was 0.68 (HR: 0.68; 95% CI: 0.45, 1.02) on progression-free survival (PFS) and 1.24 (OR: 1.24; 95% CI: 0.66, 2.32) on disease progression (DP), and these relationships were statistically non-significant. Conclusion: The OS of RCC patients was 35% higher in statin users than in non-users. However, no relationship between statin usage and the incidence risk of RCC was found. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (CRD42023393647).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Renal Injury Prevention
Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
36
期刊介绍: The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信